ESRD PPS Explained: End Stage Renal Disease Prospective Payment System
The End-Stage Renal Disease Prospective Payment System, is how Medicare pays dialysis facilities. ERSD PPS functions as a single bundled rate per treatment that covers renal dialysis services, drugs, labs, and supplies. For CY2026, the base rate is $281.71 per treatment, adjusted for patient case-mix and facility-level factors such as the wage index and low-volume status.
This guide breaks down what's included in the ESRD bundle, how the per-treatment base rate is set, the adjustments that move the final payment, and the outlier and add-on policies.
📦 What's included in the ESRD PPS bundled payment
The defining feature of the ESRD PPS is the bundled payment: instead of billing separately for each item in a dialysis session, the facility receives a single payment per treatment that covers the full set of renal dialysis services. The bundle includes:
The dialysis treatment itself.
Drugs and biologicals used to treat ESRD. Phosphate binders are currently paid through a transitional drug add-on rather than out of the base rate.
Laboratory tests related to the dialysis treatment.
Supplies and equipment used to furnish dialysis.
Home and self-dialysis training, and home dialysis support services.
By packaging these into a single rate, the ESRD PPS pays for the complete dialysis treatment rather than its individual components, encouraging efficient, coordinated care.
One common misunderstanding: physician services are not in the bundle. The monthly capitation payment for the managing physician is paid separately under the Physician Fee Schedule.
💰 The ESRD PPS per-treatment base rate
ESRD PPS pays a base rate per treatment, applied to each covered dialysis session. Medicare pays for up to three treatments per week. Additional treatments are payable when medically justified, documented, and billed with the KX modifier. Home and peritoneal dialysis are paid on a three-treatments-per-week equivalent basis, regardless of how many exchanges or sessions the patient actually performs.
CMS sets and updates the ESRD PPS base rate each calendar year. The base rate is the starting point that the case-mix and facility adjustments then modify.
🧑⚕️ Patient case-mix and facility adjustments
The base rate is adjusted so payment better reflects the cost of treating a given patient at a given facility.
Patient-level adjustments for adults account for:
Five age categories
Body surface area
Low body mass index
The onset of dialysis
Four comorbidity categories (pericarditis, gastrointestinal tract bleeding, hereditary hemolytic or sickle cell anemia, and myelodysplastic syndrome.)
Pediatric patients are also adjusted on two age categories (under 13 and 13 to 17) crossed with dialysis modality (peritoneal or hemodialysis). Pediatric patients also receive the transitional pediatric ESRD add-on payment adjustment (TPEAPA), equal to 30% of the per-treatment payment amount. This adjustment applies for CY2024 through CY2026 and is in its final year.
Facility-level adjustments include:
Wage index, which adjusts the labor-related share of the rate for local wage levels. The CY2026 labor-related share is 55.2%. A wage index floor of 0.6 applies, and year-over-year decreases are capped at 5%.
Low-volume adjustment, for facilities furnishing fewer than 4,000 treatments in each of the three preceding cost-reporting years, with no change of ownership in that window. Treatments at commonly owned facilities within five road miles count toward the total, the facility must attest to its MAC by November 1 each year, and the adjustment applies to adult treatments only.
Rural adjustment, which recognizes the added cost of furnishing dialysis in rural areas. Facilities redesignated from rural to urban under the current OMB delineations are on a phase-out schedule and receive a reduced adjustment in CY2026, ending in CY2027.
Non-contiguous area payment adjustment (NAPA), new for CY2026, which adjusts the non-labor portion of the base rate for facilities in Alaska, Hawaii, Guam, American Samoa, and the Northern Mariana Islands.
Home and self-dialysis training add-on, a wage-adjusted amount per training treatment.
The wage index and the facility- and patient-level adjustments are applied budget-neutrally, so adding or changing one shifts payment among facilities rather than increasing total spending. That is why introducing NAPA came with an offsetting reduction to the base rate. The drug and equipment add-ons described below are not budget-neutral.
📌 Outlier policy and TDAPA/TPNIES add-ons
Beyond the adjusted base rate, the ESRD PPS includes several mechanisms for unusually costly care and new technology:
Outlier payments provide additional payment when a patient's costs for eligible items exceed a set threshold, protecting facilities from catastrophic losses on high-cost cases. Eligibility is narrower than the full bundle. It covers drugs, labs, and supplies that were, or would have been, separately billable under Part B before January 1, 2011; certain drugs formerly covered under Part D, including oral-only drugs since January 1, 2025; and, also since January 1, 2025, drugs and biologicals that are composite rate services. The automated multi-channel chemistry lab panel is excluded, as are items still within their TDAPA or TPNIES payment period. Medicare pays 80% of the amount above the threshold, and the thresholds differ for adult and pediatric patients.
TDAPA (Transitional Drug Add-on Payment Adjustment) is a temporary additional payment supporting certain new renal dialysis drugs and biologicals as they enter the market, before their cost is reflected in the base rate. For a drug in an existing ESRD PPS functional category, TDAPA runs for two years. For a drug in a new functional category, it runs at least two years, and the base rate is modified afterward.
TPNIES (Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies) is a temporary add-on available for qualifying new equipment and supplies used to furnish dialysis, lasting two years. No applications were submitted for CY2026, so no items are currently being paid under it.
✅ Quality and model adjustments
Two things sit outside the payment calculation but change what a facility is actually paid.
The ESRD Quality Incentive Program (QIP) reduces payments by up to 2% based on quality performance, with a 0.5% reduction for every 10 points a facility's total performance score falls below the minimum.
The ESRD Treatment Choices (ETC) Model was terminated early, effective December 31, 2025. Its home dialysis and performance payment adjustments applied only to claims with dates of service through that date and no longer affect payment. The Kidney Care Choices model continues: the Kidney Care First (KCF) option terminated December 31, 2025, while the Comprehensive Kidney Care Contracting (CKCC) options (Graduated, Professional, and Global) were extended through December 31, 2027.
💵 Pricing new ESRD PPS claims accurately
Every input in an ESRD claim has to be accurate to updated CMS ruling for payment to be right. Because CMS updates the base rate, adjusters, and add-on policies every calendar year, and because the bundle itself is still absorbing oral-only drugs, keeping ESRD pricing accurate is an ongoing effort.
Micro-Dyn's ESRD pricing logic maintains the current base rate, adjustments, and add-ons so each claim prices against the correct methodology. Wondering how well your organization is doing with ESRD Payment methodologies? Check out our Healthcare Claims and Pricing Compliance Checklist. Learn how ESRD PPS fits into the broader Medicare payment landscape with our simple guide to CMS Ebook.
If you're considering making a switch, you can learn how Micro-Dyn prices ESRD alongside IPPS, OPPS/APC, ASC, SNF, IRF, HH, and IPF when you request a trial here.
Comments